-
Mashup Score: 32De-escalation versus shortening of DAPT - 2 month(s) ago
Mattia Galli, Francesco Costa, Eliano Pio Navarese; De-escalation versus shortening of DAPT, European Heart Journal – Cardiovascular Pharmacotherapy, , pvae019,
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: eurointervention.pcronline.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
AbstractAims. The aim of this study was to evaluate the efficacy and safety of prasugrel dose de-escalation therapy in patients with diabetes mellitus (DM)–acut
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
AbstractBackground. Guidelines recommend extended dual antiplatelet therapy (DAPT), including ticagrelor 60 mg twice daily, in high-risk post myocardial infarct
Source: academic.oup.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
AbstractAims. The relative safety and efficacy of de-escalation, extended duration (ED) (>12-months), and standard dual antiplatelet therapy for 12-months (D
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Dual antiplatelet therapy: optimal timing, management, and duration - 8 month(s) ago
Abstract. Platelet activation and aggregability play a key role in the genesis of arterial thrombus secondary to plaque rupture. For coronary patients, inhibiti
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting - 8 month(s) ago
We read with great interest the SWEDEHEART report by Tjerkaski et al.1 regarding the comparison of ticagrelor vs. clopidogrel in patients with myocardial infarc
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 012-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT - 8 month(s) ago
August 30, 2023 — BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro Missiondrug-eluting stent (DES) compared to Resolute Onyx DES (p
Source: www.dicardiology.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1ESC Congress 2023 - STOPDAPT-3: an aspirin-free antithrombotic strategy for percutaneous coronary intervention - 8 month(s) ago
Aaysha Cader interviews Masahiro Natsuaki: Prasugrel monotherapy after PCI with drug-eluting stents was not superior to DAPT for major bleeding but was non-inferior for cardiovascular events in patients with acute coronary syndrome or high bleeding risk.
Source: www.pcronline.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 8ESC Congress 2023: BIOFLOW DAPT - Biodegradable polymer SES versus durable polymer ZES in HBR subjects with 1-month DAPT - 8 month(s) ago
Nicola Ryan provides her take on the final results of the BIOFLOW DAPT – Biodegradable polymer SES versus durable polymer ZES in HBR subjects with 1-month DAPT
Source: www.pcronline.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
De-escalation versus shortening of #DAPT https://t.co/0T5uXvWb5y